Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10811426 | 0.85 | CA1 (0.54) | CA1CA2CA4KMT2ACYP3A4 | |
| SCHEMBL7979 | 0.76 | TRPA1 (0.39) | KMT2A | |
| SCHEMBL452781 | 0.76 | TRPA1 (0.39) | KMT2A | |
| SCHEMBL1760669 | 0.76 | TRPA1 (0.39) | KMT2A | |
| SCHEMBL20608621 | 0.75 | CA1 (0.38) | CA1CA2CA4KMT2A | |
| SCHEMBL812088 | 0.75 | CA1 (0.38) | CA1CA2CA4KMT2A | |
| SCHEMBL20502649 | 0.74 | CA1 (0.41) | CA1CA2CA4KMT2ATLR4 | |
| Water SCHEMBL2851760 | 0.73 | TRPA1 (0.37) | — | |
| Ammonia Solution, Strong SCHEMBL5944185 | 0.73 | TRPA1 (0.37) | — | |
| Hydrochloric Acid SCHEMBL6863594 | 0.73 | TRPA1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 738 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122042911-A | Method and system for predicting quality of radix curcumae based on morphology and chromaticity | 浙江中医药大学中药饮片有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-119655284-B | Application of solidago canadensis chemosensory substance in inhibiting red tide isokinetic algae | 浙江大学衢州研究院 | 2025-06-13 | — | — | CN | claimed |
| CN-119856666-A | Planting method for promoting high yield of eggplants | 云南省农业科学院园艺作物研究所 | 2025-04-22 | — | — | CN | claimed |
| CN-119818627-A | A Chinese medicinal composition for treating candidiasis | 沈阳药科大学 | 2025-04-15 | — | — | CN | claimed |
| CN-119798112-A | Preparation and application of NMDA receptor inhibitor based on germacrone skeleton | 沈阳药科大学 | 2025-04-11 | — | — | CN | claimed |
| CN-115932070-B | Method for detecting non-volatile chemical components in Xingnaojing injection | 无锡济煜山禾药业股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119700729-A | Application of germacrone and medicine thereof | 暨南大学 | 2025-03-28 | — | — | CN | claimed |
| CN-119655284-A | Application of solidago canadensis chemosensory substance in inhibiting red tide isokinetic algae | 浙江大学衢州研究院 | 2025-03-21 | — | — | CN | claimed |
| US-20060051438-A1 | Herbal medicaments for the treatment of neurocerebrovascular disorders | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2006-03-09 | — | — | US | claimed |
| US-6991814-B2 | Herbal medicaments for the treatment of neurocerebrovascular disorders | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-01-31 | — | — | US | claimed |
| WO-2005105059-A1 | PERMEATION ENHANCER COMPRISING GENUS CURCUMA OR GERMACRONE FOR TRANSDERMAL AND TOPICAL ADMINISTRATION OF ACTIVE AGENTS | ANTARES PHARMA IPL AG (CH) | 2005-11-10 | — | — | WO | claimed |
| US-20050244522-A1 | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents | MMV FINANCIAL INC. (CA) | 2005-11-03 | — | — | US | claimed |
| CN-1615144-A | A composition for treating neurocerebrovascular disorders | COUNCIL SCIENT IND RES (IN) | 2005-05-11 | — | — | CN | claimed |
| EP-1453528-A2 | COMPOSITIONS CONTAINING CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS | Council of Scientific and Industrial Research (IN) | 2004-09-08 | — | — | EP | claimed |
| US-20040033277-A1 | Herbal medicaments for the treatment of neurocerebrovascular disorders | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2004-02-19 | — | — | US | claimed |
| WO-2003051380-A2 | COMPOSITIONS CONTAINEING CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-06-26 | — | — | WO | claimed |
| EP-1301194-A1 | ESSENTIAL OIL COMBINATION AND THERAPEUTIC USES THEREOF | Giraud, Anne Marie Pierrette (FR) | 2003-04-16 | — | — | EP | claimed |
| WO-2002007744-A1 | ESSENTIAL OIL COMBINATION AND THERAPEUTIC USES THEREOF | GIRAUD ANNE MARIE PIERRETTE (FR) | 2002-01-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | CA1 290/4885CA2 176/4885CA4 408/4885 |
| US-20060051438-A1 | Herbal medicaments for the treatment of neurocerebrovascular disorders | NR0B1, NR0B2, CYP46A1 | CA1 4163/4885CA2 4567/4885CA4 3273/4885 |
| US-20050244522-A1 | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents | TGOLN2, TMSB10, DPM1 | CA1 2289/4885CA2 3485/4885CA4 2914/4885 |
| US-20040033277-A1 | Herbal medicaments for the treatment of neurocerebrovascular disorders | NR0B1, NR0B2, CYP46A1 | CA1 4163/4885CA2 4567/4885CA4 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.